EMEA-002573-PIP02-23 - paediatric investigation plan
amivantamab
PIPHuman
Key facts
- Invented name
- Rybrevant
- Active Substance
- amivantamab
- Therapeutic area
- Neoplasms benign, malignant and unspecified (incl cysts and polyps)
- Decision number
- P/0166/2024
- PIP number
- EMEA-002573-PIP02-23
- Pharmaceutical form(s)
- All pharmaceutical forms
- Condition(s) / indication(s)
- Treatment of colorectal carcinoma
- Route(s) of administration
- All routes of administration
- Contact for public enquiries
Janssen Cilag International
Email: contact@Janssen-emea.com
Tel. +32 14602111- Decision type
- W: decision granting a waiver in all age groups for all conditions or indications
- Decision date